SYNTARA LIMITED (SNT)
Share Price Analysis and Chart

02/10/2025

1

Speculative Buy

$0.06

114.29%

Bell Potter highlights Syntara's compelling Phase 2a results for amsulostat in myelofibrosis. Patients with limited prior treatment response showed significant symptom improvement and spleen size reductions.

Half of the patients achieved a -50% or greater reduction in Total Symptom Score (TSS) and four of nine evaluable patients recording a greater than (or equal) -25% spleen reduction.

The broker believes the consistency of benefits underlines the drug’s potential and supports progression to late-stage trials.

Discussions with regulators are planned for 1H 2026 ahead of a Phase 2b trial expected to commence later in 2026. 

No material forecast changes are made, and the broker maintains a 6c target and a Speculative Buy rating.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.50 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.20 cents.

02/10/2025

1

Buy

$0.19

578.57%

Management at Syntara has released final data from its Phase I/IIa trial in myelofibrosis, incorporating outcomes from seven patients, with efficacy and safety signals continuing to differentiate amsulostat, explains Canaccord Genuity. No serious adverse events were reported.

Amsulostat is an oral small-molecule drug which irreversibly inhibits the lysyl oxidase family of enzymes, which play a key role in fibrosis through cross-linking of collagen and elastin in the extracellular matrix.

The analysts highlight upcoming catalysts including Phase IIb trial design confirmation in the first half of 2026, and interim readouts in myelodysplastic syndromes from mid-2026.

Pro-forma cash of around $20m funds the company into 2027, points out the broker.

Canaccord maintains its Buy rating and 19c target price.